Clinical trial · Interventional
Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma
A Multicenter, Phase III, Randomized Study to Evaluate the Efficacy of Response-adapted Strategy to Define Maintenance After Standard Chemoimmunotherapy in Patients With Advanced-stage Follicular Lymphoma.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Recently, the availability of R has substantially changed therapeutic approach to FL patients, since its combination with chemotherapy has improved response rates, progression free survival (PFS) and overall survival (OS). Based on the results of recently completed randomized studies the standard treatment for patients with FL should consist of an initial therapy with R-CHOP combination followed by two-year maintenance with R. Although results of randomized trials confirmed that this approach results in an improved patients' outcome and made a step forward in the management of patients with FL, one important question that can be raised is if this approach is really needed for all patients with FL or if some of them could benefit from a reduced intensity treatment achieving the same results in terms of outcome and survival . This question is of particular interest for newly diagnosed patients for whom maintenance does not affect OS. More recent data demonstrated that the outcome of patients with FL can be further predicted by evaluating the quality of response to therapy studying minimal residual disease (MRD). This project addresses the objective of evaluating if combining clinical response assessed on FDG-PET scan and molecular response measured through MRD detection could permit to single out groups of patients at different risk of progression and to consequently modulate maintenance therapies, with the aim to provide clinicians a more rational use of the available diagnostic and therapeutic resources.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Follicular Non-Hodgkin's Lymphoma | Follicular Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ibritumomab Tiuxetan + Maintenance | Drug | — | UNRESOLVED |
| Maintenance weekly x4 | Drug | — | UNRESOLVED |
| Observation | Drug | — | UNRESOLVED |
| R-CHOP or R-bendamustine | Drug | — | UNRESOLVED |
| Standard Maintenance | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- OTHER
- label
- GROUP 1 - STANDARD
- description
- R-CHOP or R-bendamustine + Standard Maintenance
- interventionNames
- Drug: R-CHOP or R-bendamustine
- Drug: Standard Maintenance
- type
- EXPERIMENTAL
- label
- GROUP 2
- description
- FDG-PET POSITIVE (score 4-5) patients (High risk) R-CHOP or R-bendamustine + Ibritumomab Tiuxetan + Maintenance
- interventionNames
- Drug: R-CHOP or R-bendamustine
- Drug: Ibritumomab Tiuxetan + Maintenance
- type
- EXPERIMENTAL
- label
- GROUP 1a
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histological diagnosis of B-Cell CD20+ Follicular Lymphoma (FL), grade I, II, IIIa according to the WHO 2008 classification * ECOG performance status 0-2 * Age ≥ 18 years * Ann Arbor stage II-IV * FLIPI2\>0 * Presence of evaluable/measurable disease after diagnostic biopsy * At least one of the following criteria for defining active disease: * systemic symptoms * cytopenia due to bone marrow involvement * LDH\> upper normal value * any nodal or extranodal tumor mass with a diameter \>7cm * involvement of ≥ 3 nodal sites, each with a diameter of ≥ 3cm * extranodal disease * rapidly progressive disease * Life expectancy \> 6 months * Left ventricular ejection fraction (LVEF) ³ 50% * Serum negativity for HIV * Serum negativity for HBsAg; HBcAb positive but HBV-DNA negative patients are allowed with mandatory Lamivudine prophylaxis. * Serum negativity for HCV, except for those patients without signs of active viral replication assessed by HCV-RNA copies * Serum creatinine \< 2mg/dl , serum bilirubin \< 1.5mg/dl, aspartate amino-transferase (AST/GOT) £ 2.5xUNV, alanine amino-transferase (ALT/GPT) £ 2.5xUNV, and alkaline phosphatase £ 4 times the upper limit of normal (unless the increase is attributed directly to the presence of tumour by the Investigator) * Patients with no previous treatment for the lymphoma with the exception of locoregional radiotherapy (IFRT) * Adequate measure adoption to avoid pregnancy * Written informed consent given at time of registration * Patient must be accessible for treatment and follow up. Exclusion Criteria: * Histological diagnosis of : * any lymphoma other than follicular lymphoma and all CD20 negative B-cell lymphomas * grade III b follicular lymphoma * evidence of transformation to high grade lymphoma * Ann Arbor stage I * Suspect or clinical evidence of CNS involvement by lymphoma * History of other malignancies within 5 years prior to study entry except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer, low grade, early stage localized prostate cancer treated surgically with curative intent, good prognosis DCIS of the breast treated with lumpectomy alone with curative intent * Evidence of any severe active acute or chronic infection * Concurrent co-morbid medical condition which might exclude administration of full dose chemotherapy * Severe chronic obstructive pulmonary disease with hypoxemia * Severe diabetes mellitus difficult to control with adequate insulin therapy * Myocardial infarction within 6 months before study entry * Clinically significant secondary cardiovascular disease e.g. uncontrolled hypertension, (resting diastolic blood pressure \>115 mmHg), uncontrolled multifocal cardiac arrhythmias, symptomatic angina pectoris or congestive cardiac failure NYHA class III-IV * HbsAg-positive, HIV-positive, or HCVAb-positive patients * Known hypersensitivity or anaphylactic reactions to murine antibodies or proteins * Any other co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent * Follicular lymphoma, showing a negative baseline PET scan.
References
Publications (2)
- DERIVEDDurmo R, Chauvie S, Fallanca F, Bergesio F, Pinto A, Del Giudice I, Coscia M, Corradini P, Angelucci E, Tosi P, Freilone R, Ballerini F, Bari A, Pastore D, Zinzani PL, Bolis S, Flenghi L, Liso A, Olivieri J, Marcheselli L, Merli M, Versari A, Guerra L, Luminari S. Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi. Blood Adv. 2025 Jun 24;9(12):2927-2934. doi: 10.1182/bloodadvances.2024014790. PMID 40106688
- DERIVEDLuminari S, Manni M, Galimberti S, Versari A, Tucci A, Boccomini C, Farina L, Olivieri J, Marcheselli L, Guerra L, Ferrero S, Arcaini L, Cavallo F, Kovalchuk S, Skrypets T, Del Giudice I, Chauvie S, Patti C, Stelitano C, Ricci F, Pinto A, Margiotta Casaluci G, Zilioli VR, Merli A, Ladetto M, Bolis S, Pavone V, Chiarenza A, Arcari A, Anastasia A, Dondi A, Mannina D, Federico M; Fondazione Italiana Linfomi. Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. J Clin Oncol. 2022 Mar 1;40(7):729-739. doi: 10.1200/JCO.21.01234. Epub 2021 Oct 28. PMID 34709880